---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-008773"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-08-13T21:21:36+00:00"
generated_at: "2026-08-13T21:22:12.548212+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# NeOnc discusses NEO100-01 Phase 2a results; no data in filing excerpt

## Summary
- Hosted investor call on Aug 12, 2026 to discuss Phase 2a top-line results of NEO100-01 in recurrent IDH1 mutant high-grade glioma.
- Participants included CEO Amir Heshmatpour, CFO Keithly Garnett, CSO Thomas Chen, and Chief Clinical Officer Josh Neman.
- Provided transcript does not include specific efficacy or safety data; only call introduction is in the exhibit.

## SEC filing metadata
- accession: 0001829126-26-008773
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-08-13T21:21:36+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626008773/0001829126-26-008773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626008773/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-008773
- JSON: https://secwatch.observer/filing/0001829126-26-008773.json
- Plain text: https://secwatch.observer/filing/0001829126-26-008773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.